Journal of Obesity & Metabolic Syndrome最新文献_第6页

The Prevalence of Abdominal Obesity and Metabolic Syndrome in Korean Children and Adolescents. 韩国儿童和青少年腹部肥胖和代谢综合征的患病率。

IF 5.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Obesity & Metabolic Syndrome

Pub Date : 2023-06-30 DOI: 10.7570/jomes23025

Ja Hyang Cho

J Obes Metab Syndr 2023;32:103-105 Metabolic syndrome (MetS) is an emerging burden associated with significant morbidity and mortality in children and adolescents. In recent decades, the prevalence of obesity has continually increased both worldwide and in Korea.1,2 Trends in mean body mass index (BMI) have recently flattened for both boys and girls in northwestern Europe and Asia-Pacific regions, for boys in southwestern Europe, and for girls in central and Latin America.1 In contrast, the rise in BMI has accelerated for both boys and girls in east and South Asia, and for boys in Southeast Asia.1 Pediatric obesity is often accompanied by MetS. Consequently, accurate evaluation of obesity in children and adolescents is of significant interest because it may result in adulthood obesity and comorbid conditions such as cardiovascular disease, obstructive sleep apnea, insulin resistance, non-alcoholic fatty liver disease, and dyslipidemia.3,4 More than half of all obese children have two or more complications. The definition of MetS by the modified criteria of the National Cholesterol Education Program-Adult Treatment Panel III must include at least three of five criteria: central obesity above the 90th percentile, fasting glucose above 110 mg/dL, hypertriglycerides above 110 mg/dL, low high density lipoprotein cholesterol below 40 mg/dL, and hypertension above the 90th percentile or receiving treatment for hypertension.1 Based on the criteria of the International Diabetes Federation, MetS is a combination of central obesity with the presence of two or more of the other four risk factors.5 According to International Diabetes Federation guidelines, children younger than 6 years are excluded from the definition due to limited data for this age group. MetS cannot be diagnosed at the age of 6 to 10 years. However, additional testing should be performed if there is a family history of MetS, type 2 diabetes mellitus, dyslipidemia, cardiovascular disease, hypertension, or obesity.6 Most studies are based on baseline BMI measurements to evaluate excessive adiposity in humans. BMI is a limited indicator of pediatric metabolic risk due to the paucity of data in this population.7 Waist circumference (WC) and waist-height ratio (WHtR) are helpful measures of central adiposity in both clinical and research settings.8 WC has emerged as an index of pediatric adiposity that predicts fat mass as effectively as or better than BMI.8 Moreover, WC has been shown to be effective in estimating total adiposity, which is strongly linked to intra-abdominal fat. Several studies have investigated the prevalence of abdominal obesity in children and adolescents and report that it ranges from 9.7% to 11.5% in Korea.9-11 Compared with previous studies,9-11 the

{"title":"The Prevalence of Abdominal Obesity and Metabolic Syndrome in Korean Children and Adolescents.","authors":"Ja Hyang Cho","doi":"10.7570/jomes23025","DOIUrl":"https://doi.org/10.7570/jomes23025","url":null,"abstract":"J Obes Metab Syndr 2023;32:103-105 Metabolic syndrome (MetS) is an emerging burden associated with significant morbidity and mortality in children and adolescents. In recent decades, the prevalence of obesity has continually increased both worldwide and in Korea.1,2 Trends in mean body mass index (BMI) have recently flattened for both boys and girls in northwestern Europe and Asia-Pacific regions, for boys in southwestern Europe, and for girls in central and Latin America.1 In contrast, the rise in BMI has accelerated for both boys and girls in east and South Asia, and for boys in Southeast Asia.1 Pediatric obesity is often accompanied by MetS. Consequently, accurate evaluation of obesity in children and adolescents is of significant interest because it may result in adulthood obesity and comorbid conditions such as cardiovascular disease, obstructive sleep apnea, insulin resistance, non-alcoholic fatty liver disease, and dyslipidemia.3,4 More than half of all obese children have two or more complications. The definition of MetS by the modified criteria of the National Cholesterol Education Program-Adult Treatment Panel III must include at least three of five criteria: central obesity above the 90th percentile, fasting glucose above 110 mg/dL, hypertriglycerides above 110 mg/dL, low high density lipoprotein cholesterol below 40 mg/dL, and hypertension above the 90th percentile or receiving treatment for hypertension.1 Based on the criteria of the International Diabetes Federation, MetS is a combination of central obesity with the presence of two or more of the other four risk factors.5 According to International Diabetes Federation guidelines, children younger than 6 years are excluded from the definition due to limited data for this age group. MetS cannot be diagnosed at the age of 6 to 10 years. However, additional testing should be performed if there is a family history of MetS, type 2 diabetes mellitus, dyslipidemia, cardiovascular disease, hypertension, or obesity.6 Most studies are based on baseline BMI measurements to evaluate excessive adiposity in humans. BMI is a limited indicator of pediatric metabolic risk due to the paucity of data in this population.7 Waist circumference (WC) and waist-height ratio (WHtR) are helpful measures of central adiposity in both clinical and research settings.8 WC has emerged as an index of pediatric adiposity that predicts fat mass as effectively as or better than BMI.8 Moreover, WC has been shown to be effective in estimating total adiposity, which is strongly linked to intra-abdominal fat. Several studies have investigated the prevalence of abdominal obesity in children and adolescents and report that it ranges from 9.7% to 11.5% in Korea.9-11 Compared with previous studies,9-11 the","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 2","pages":"103-105"},"PeriodicalIF":5.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/07/f2/jomes-32-2-103.PMC10327683.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9764450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter: Triglyceride-Glucose Index Predicts Cardiovascular Outcome in Metabolically Unhealthy Obese Population: A Nationwide Population-Based Cohort Study (J Obes Metab Syndr 2022;31:178-86). 甘油三酯-葡萄糖指数预测代谢不健康肥胖人群的心血管结局:一项全国性的基于人群的队列研究(J Obes Metab Syndr 2022;31:178-86)。

IF 5.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Obesity & Metabolic Syndrome

Pub Date : 2023-06-30 DOI: 10.7570/jomes23017

Gwanpyo Koh

J Obes Metab Syndr 2023;32:179-180 Cardiovascular diseases (CVDs) are the most common cause of physical disability and mortality globally1 and the second leading cause of death in Korea.2 Hence, determining predictors of CVD is crucial to promoting human health. Currently, traditional cardiovascular (CV) risk factors are used in CVD prediction models.3 In addition to diabetes mellitus (DM), insulin resistance is the fundamental etiology of atherosclerotic CVD and is used to predict CVD in both people with and without DM.4 The gold standard for diagnosis of insulin resistance is the euglycemic insulin clamp technique; however, this method is complex, invasive, and costly.5 The homeostasis model assessment-estimated insulin resistance index is widely used owing to its convenience; only one blood sample is required. However, it has the following drawbacks: (1) blood insulin concentration must be measured; (2) it cannot be used for individuals receiving insulin therapy; and (3) it is inaccurate in patients with DM with diminished beta-cell function.6 The triglyceride-glucose (TyG) index overcomes these drawbacks. It is calculated using fasting glucose and triglyceride levels and can be used to indicate insulin resistance in people with and without DM.7 Cho et al.8 classified 292,206 participants of the Korean National Health Insurance Service National Health Screening Cohort into four groups (metabolically healthy non-obese, metabolically unhealthy non-obese, metabolically healthy obese [MHO], and metabolically unhealthy obese [MUO]) that were followed from 2009 to 2015. The baseline TyG index was found to be correlated with CV events and CV mortality in the MUO group. However, this study analyzed the correlation between baseline TyG index and the incidence of CVD over 6 years of follow-up. Changes in the TyG index during the follow-up period may have influenced the gradual onset of CVD. Therefore, predicting CVD based on TyG index taken at one time point may be inaccurate and vulnerable to regression dilution biases.9 Furthermore, Cho et al.8 divided the participants into groups based on obesity and metabolic health at baseline to investigate CV events and mortality throughout the follow-up period. Obesity and metabolic health also change over time. Soriguer et al.10 reported that many study participants progressed from MHO to MUO during a 6or 11-year of follow-up. Furthermore, the incidence of type 2 DM decreased among individuals who lost weight during the follow-up period. Thus, obesity and metabolic health are dynamic and change over time, and ultimately,

{"title":"Letter: Triglyceride-Glucose Index Predicts Cardiovascular Outcome in Metabolically Unhealthy Obese Population: A Nationwide Population-Based Cohort Study (J Obes Metab Syndr 2022;31:178-86).","authors":"Gwanpyo Koh","doi":"10.7570/jomes23017","DOIUrl":"https://doi.org/10.7570/jomes23017","url":null,"abstract":"J Obes Metab Syndr 2023;32:179-180 Cardiovascular diseases (CVDs) are the most common cause of physical disability and mortality globally1 and the second leading cause of death in Korea.2 Hence, determining predictors of CVD is crucial to promoting human health. Currently, traditional cardiovascular (CV) risk factors are used in CVD prediction models.3 In addition to diabetes mellitus (DM), insulin resistance is the fundamental etiology of atherosclerotic CVD and is used to predict CVD in both people with and without DM.4 The gold standard for diagnosis of insulin resistance is the euglycemic insulin clamp technique; however, this method is complex, invasive, and costly.5 The homeostasis model assessment-estimated insulin resistance index is widely used owing to its convenience; only one blood sample is required. However, it has the following drawbacks: (1) blood insulin concentration must be measured; (2) it cannot be used for individuals receiving insulin therapy; and (3) it is inaccurate in patients with DM with diminished beta-cell function.6 The triglyceride-glucose (TyG) index overcomes these drawbacks. It is calculated using fasting glucose and triglyceride levels and can be used to indicate insulin resistance in people with and without DM.7 Cho et al.8 classified 292,206 participants of the Korean National Health Insurance Service National Health Screening Cohort into four groups (metabolically healthy non-obese, metabolically unhealthy non-obese, metabolically healthy obese [MHO], and metabolically unhealthy obese [MUO]) that were followed from 2009 to 2015. The baseline TyG index was found to be correlated with CV events and CV mortality in the MUO group. However, this study analyzed the correlation between baseline TyG index and the incidence of CVD over 6 years of follow-up. Changes in the TyG index during the follow-up period may have influenced the gradual onset of CVD. Therefore, predicting CVD based on TyG index taken at one time point may be inaccurate and vulnerable to regression dilution biases.9 Furthermore, Cho et al.8 divided the participants into groups based on obesity and metabolic health at baseline to investigate CV events and mortality throughout the follow-up period. Obesity and metabolic health also change over time. Soriguer et al.10 reported that many study participants progressed from MHO to MUO during a 6or 11-year of follow-up. Furthermore, the incidence of type 2 DM decreased among individuals who lost weight during the follow-up period. Thus, obesity and metabolic health are dynamic and change over time, and ultimately,","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 2","pages":"179-180"},"PeriodicalIF":5.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/19/jomes-32-2-179.PMC10327687.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9817523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response: Triglyceride-Glucose Index Predicts Cardiovascular Outcome in Metabolically Unhealthy Obese Population: A Nationwide Population-Based Cohort Study (J Obes Metab Syndr 2022;31:178-86). 甘油三酯-葡萄糖指数预测代谢不健康肥胖人群心血管结局:一项基于全国人群的队列研究[J] .中国医学杂志，2022;31:178-86)。

IF 5.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Obesity & Metabolic Syndrome

Pub Date : 2023-06-30 DOI: 10.7570/jomes23019

Yun Kyung Cho, Hwi Seung Kim, Joong-Yeol Park, Woo Je Lee, Ye-Jee Kim, Chang Hee Jung

J Obes Metab Syndr 2023;32:181-182 The triglyceride glucose (TyG) index is considered a surrogate marker of cardiovascular disease (CVD) and mortality using the parameter of insulin resistance. Numerous studies have investigated the associations between the TyG index and cardiovascular outcomes, including cardiovascular mortality. A recent meta-analysis and systematic review evaluated associations between the TyG index and the risks of CVD and mortality in the general population.1 Twelve cohort studies involving 6,354,990 participants were analyzed. Higher TyG index values were significantly associated with an increased incidence of CVD; however, the TyG index was not correlated with mortality, including cardiovascular mortality in analyses.1 A subgroup analysis of the population without diabetes revealed no significant association between myocardial infarction incidence and the TyG index, indicating the heterogeneous implications of this index across populations.2 The present study contributes to the literature because we focused on the specific population in which the TyG index could be a useful surrogate marker for an elevated CVD risk.3 Our results demonstrated that the TyG index could predict CVD mortality only in participants with metabolically unhealthy obesity (MUO), and that the index is substantially and consistently associated with CVD regardless of the metabolic health phenotype or presence of obesity.3 In a letter to the editor, the author stated that assessing the predictive value of the TyG index for CVD outcomes would provide greater benefit if we considered changes in the TyG index as well as the obese metabolic health phenotype. Several recent studies have reported the significant effect of longitudinal changes in the TyG index on CVD risk. We appreciate the letter author for highlighting these important points. A study involving 62,443 healthy Chinese people found that CVD risk increased with quartile of change in the TyG index during a median follow-up of 7.01 years, and that adding change in the TyG index to a baseline risk model for CVD improved its predictive power.4 Another prospective cohort study involving 36,359 participants with a median observation period of

{"title":"Response: Triglyceride-Glucose Index Predicts Cardiovascular Outcome in Metabolically Unhealthy Obese Population: A Nationwide Population-Based Cohort Study (J Obes Metab Syndr 2022;31:178-86).","authors":"Yun Kyung Cho, Hwi Seung Kim, Joong-Yeol Park, Woo Je Lee, Ye-Jee Kim, Chang Hee Jung","doi":"10.7570/jomes23019","DOIUrl":"https://doi.org/10.7570/jomes23019","url":null,"abstract":"J Obes Metab Syndr 2023;32:181-182 The triglyceride glucose (TyG) index is considered a surrogate marker of cardiovascular disease (CVD) and mortality using the parameter of insulin resistance. Numerous studies have investigated the associations between the TyG index and cardiovascular outcomes, including cardiovascular mortality. A recent meta-analysis and systematic review evaluated associations between the TyG index and the risks of CVD and mortality in the general population.1 Twelve cohort studies involving 6,354,990 participants were analyzed. Higher TyG index values were significantly associated with an increased incidence of CVD; however, the TyG index was not correlated with mortality, including cardiovascular mortality in analyses.1 A subgroup analysis of the population without diabetes revealed no significant association between myocardial infarction incidence and the TyG index, indicating the heterogeneous implications of this index across populations.2 The present study contributes to the literature because we focused on the specific population in which the TyG index could be a useful surrogate marker for an elevated CVD risk.3 Our results demonstrated that the TyG index could predict CVD mortality only in participants with metabolically unhealthy obesity (MUO), and that the index is substantially and consistently associated with CVD regardless of the metabolic health phenotype or presence of obesity.3 In a letter to the editor, the author stated that assessing the predictive value of the TyG index for CVD outcomes would provide greater benefit if we considered changes in the TyG index as well as the obese metabolic health phenotype. Several recent studies have reported the significant effect of longitudinal changes in the TyG index on CVD risk. We appreciate the letter author for highlighting these important points. A study involving 62,443 healthy Chinese people found that CVD risk increased with quartile of change in the TyG index during a median follow-up of 7.01 years, and that adding change in the TyG index to a baseline risk model for CVD improved its predictive power.4 Another prospective cohort study involving 36,359 participants with a median observation period of","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 2","pages":"181-182"},"PeriodicalIF":5.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/21/64/jomes-32-2-181.PMC10327682.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9764449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Novel Anthropometric Parameter, Weight-Adjusted Waist Index Represents Sarcopenic Obesity in Newly Diagnosed Type 2 Diabetes Mellitus. 一种新的人体测量参数，体重调整腰围指数代表新诊断的2型糖尿病的肌肉减少性肥胖。

IF 5.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Obesity & Metabolic Syndrome

Pub Date : 2023-06-30 DOI: 10.7570/jomes23005

Min Jeong Park, Soon Young Hwang, Nam Hoon Kim, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo

Background: As the metabolic significance of sarcopenic obesity (SO) is revealed, finding an appropriate index to detect SO is important, especially for type 2 diabetes mellitus (T2DM) patients with accompanying metabolic dysfunction.

Methods: Participants (n=515) from the Korea Guro Diabetes Program were included to compare how well waist circumference (WC), waist hip ratio (WHR), waist height ratio (WHtR), and the weight-adjusted waist index (WWI) predict SO in newly diagnosed T2DM patients. Sarcopenia was defined based on guidelines from the 2019 Asian Working Group for Sarcopenia as both low muscle mass (appendicular skeletal muscle [ASM]/height² <7.0 kg/m² for men, <5.4 kg/m² for women) and strength (handgrip strength <28.0 kg for men, <18.0 kg for women) and/or reduced physical performance (gait speed <1.0 m/sec). Obesity was defined as a WC ≥90 cm in men and ≥85 cm in women. The WHR, WHtR, and WWI were calculated by dividing the WC by the hip circumference, height, and √ weight, respectively.

Results: The WC, WHR, and WHtR correlated positively with the fat and muscle mass represented by truncal fat amount (TFA) and ASM, whereas the WWI was proportional to the TFA and inversely related to ASM. Of the four indices, the WWI showed the highest area under the receiver operative characteristic curve for SO. The WWI also exhibited a positive correlation with albuminuria and the mean brachial-ankle pulse wave velocity, especially in patients aged ≥65 years.

Conclusion: The WWI is the preferable anthropometric index for predicting SO in T2DM patients, and it might be a proper index for predicting cardiometabolic risk factors in elderly people.

背景:随着肌少性肥胖(SO)的代谢意义的揭示，寻找合适的指标检测SO非常重要，特别是对于伴有代谢功能障碍的2型糖尿病(T2DM)患者。方法:纳入韩国古罗糖尿病项目的参与者(n=515)，比较腰围(WC)、腰臀比(WHR)、腰高比(WHtR)和体重调整腰围指数(WWI)对新诊断T2DM患者SO的预测效果。根据2019年亚洲肌少症工作组的指南，肌少症被定义为低肌肉量(男性尾骨骼肌[ASM]/身高2 2，女性2)和力量(握力)。结果:WC、WHR和WHtR与躯干脂肪量(TFA)和ASM所代表的脂肪和肌肉量呈正相关，而WWI与TFA成正比，与ASM呈负相关。在四个指标中，WWI在SO的接受者工作特征曲线下显示的面积最大。WWI也与蛋白尿和平均臂踝脉波速度呈正相关，尤其是在年龄≥65岁的患者中。结论:WWI是预测T2DM患者SO的较好人体测量指标，可能是预测老年人心脏代谢危险因素的较好指标。

{"title":"A Novel Anthropometric Parameter, Weight-Adjusted Waist Index Represents Sarcopenic Obesity in Newly Diagnosed Type 2 Diabetes Mellitus.","authors":"Min Jeong Park, Soon Young Hwang, Nam Hoon Kim, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo","doi":"10.7570/jomes23005","DOIUrl":"https://doi.org/10.7570/jomes23005","url":null,"abstract":"Background: As the metabolic significance of sarcopenic obesity (SO) is revealed, finding an appropriate index to detect SO is important, especially for type 2 diabetes mellitus (T2DM) patients with accompanying metabolic dysfunction.Methods: Participants (n=515) from the Korea Guro Diabetes Program were included to compare how well waist circumference (WC), waist hip ratio (WHR), waist height ratio (WHtR), and the weight-adjusted waist index (WWI) predict SO in newly diagnosed T2DM patients. Sarcopenia was defined based on guidelines from the 2019 Asian Working Group for Sarcopenia as both low muscle mass (appendicular skeletal muscle [ASM]/height2 <7.0 kg/m2 for men, <5.4 kg/m2 for women) and strength (handgrip strength <28.0 kg for men, <18.0 kg for women) and/or reduced physical performance (gait speed <1.0 m/sec). Obesity was defined as a WC ≥90 cm in men and ≥85 cm in women. The WHR, WHtR, and WWI were calculated by dividing the WC by the hip circumference, height, and √ weight, respectively.Results: The WC, WHR, and WHtR correlated positively with the fat and muscle mass represented by truncal fat amount (TFA) and ASM, whereas the WWI was proportional to the TFA and inversely related to ASM. Of the four indices, the WWI showed the highest area under the receiver operative characteristic curve for SO. The WWI also exhibited a positive correlation with albuminuria and the mean brachial-ankle pulse wave velocity, especially in patients aged ≥65 years.Conclusion: The WWI is the preferable anthropometric index for predicting SO in T2DM patients, and it might be a proper index for predicting cardiometabolic risk factors in elderly people.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 2","pages":"130-140"},"PeriodicalIF":5.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/31/jomes-32-2-130.PMC10327688.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9751926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Temporal Trends of the Prevalence of Abdominal Obesity and Metabolic Syndrome in Korean Children and Adolescents between 2007 and 2020. 2007年至2020年韩国儿童和青少年腹部肥胖和代谢综合征患病率的时间趋势

IF 5.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Obesity & Metabolic Syndrome

Pub Date : 2023-06-30 DOI: 10.7570/jomes22059

Jieun Lee, Sung-Chan Kang, Obin Kwon, Seung-Sik Hwang, Jin Soo Moon, Hyun Wook Chae, Jaehyun Kim

Background: The prevalence of obesity in children and adolescents is increasing worldwide, which is of concern because obesity can lead to various complications such as metabolic syndrome (MS). Waist circumference (WC) and waist-height ratio (WHtR) are useful indicators of abdominal obesity and MS. In this study, we investigate trends in the prevalence of abdominal obesity and MS using two different references.

Methods: Data from the Korea National Health and Nutrition Examination Survey (2007 to 2020) were used. In total, 21,652 participants aged 2 to 18 years and 9,592 participants aged 10 to 18 years were analyzed for abdominal obesity and MS, respectively. The prevalence of abdominal obesity and that of MS were compared using the Korean National Growth Chart in 2007 (REF2007) and the newly published WC and WHtR reference values in 2022 (REF2022).

Results: Both WC and WHtR showed an increasing trend. The prevalence of abdominal obesity was 14.71% based on REF2022, 5.85% points higher than that of 8.86% based on REF2007. MS based on REF2022 had a higher prevalence for both the National Cholesterol Education Program definition (3.90% by REF2007, 4.78% by REF2022) and the International Diabetes Federation definition (2.29% by REF2007, 3.10% by REF2022). The prevalence of both abdominal obesity and MS increased over time.

Conclusion: The prevalence of abdominal obesity and MS increased in Korean children and adolescents from 2007 to 2020. When analyzed by REF2022, both abdominal obesity and MS showed higher prevalence rates than when using REF2007, indicating that previous reports were underestimated. Follow-up for abdominal obesity and MS using REF2022 is needed.

背景:世界范围内儿童和青少年肥胖的患病率正在上升，这是一个令人关注的问题，因为肥胖可导致各种并发症，如代谢综合征(MS)。腰围(WC)和腰高比(WHtR)是腹部肥胖和多发性硬化症的有用指标。在本研究中，我们使用两种不同的参考文献来研究腹部肥胖和多发性硬化症的流行趋势。方法:采用韩国国家健康与营养调查(2007 ~ 2020年)的数据。总共有21652名年龄在2至18岁之间的参与者和9592名年龄在10至18岁之间的参与者分别被分析为腹部肥胖和多发性硬化症。使用2007年韩国国家增长图表(REF2007)和新发布的2022年腰围和腰围参考值(REF2022)比较腹部肥胖和多发性硬硬症的患病率。结果:WC和WHtR均呈上升趋势。基于REF2022的腹部肥胖患病率为14.71%，比基于REF2007的8.86%高5.85%。基于REF2022的MS在国家胆固醇教育计划定义(REF2007为3.90%，REF2022为4.78%)和国际糖尿病联合会定义(REF2007为2.29%，REF2022为3.10%)中都有较高的患病率。腹部肥胖和多发性硬化症的患病率随着时间的推移而增加。结论:2007 - 2020年，韩国儿童和青少年腹部肥胖和多发性硬化症的患病率有所上升。当使用REF2022进行分析时，腹部肥胖和MS的患病率均高于使用REF2007时，这表明之前的报告被低估了。需要使用REF2022对腹部肥胖和多发性硬化症进行随访。

{"title":"Temporal Trends of the Prevalence of Abdominal Obesity and Metabolic Syndrome in Korean Children and Adolescents between 2007 and 2020.","authors":"Jieun Lee, Sung-Chan Kang, Obin Kwon, Seung-Sik Hwang, Jin Soo Moon, Hyun Wook Chae, Jaehyun Kim","doi":"10.7570/jomes22059","DOIUrl":"https://doi.org/10.7570/jomes22059","url":null,"abstract":"Background: The prevalence of obesity in children and adolescents is increasing worldwide, which is of concern because obesity can lead to various complications such as metabolic syndrome (MS). Waist circumference (WC) and waist-height ratio (WHtR) are useful indicators of abdominal obesity and MS. In this study, we investigate trends in the prevalence of abdominal obesity and MS using two different references.Methods: Data from the Korea National Health and Nutrition Examination Survey (2007 to 2020) were used. In total, 21,652 participants aged 2 to 18 years and 9,592 participants aged 10 to 18 years were analyzed for abdominal obesity and MS, respectively. The prevalence of abdominal obesity and that of MS were compared using the Korean National Growth Chart in 2007 (REF2007) and the newly published WC and WHtR reference values in 2022 (REF2022).Results: Both WC and WHtR showed an increasing trend. The prevalence of abdominal obesity was 14.71% based on REF2022, 5.85% points higher than that of 8.86% based on REF2007. MS based on REF2022 had a higher prevalence for both the National Cholesterol Education Program definition (3.90% by REF2007, 4.78% by REF2022) and the International Diabetes Federation definition (2.29% by REF2007, 3.10% by REF2022). The prevalence of both abdominal obesity and MS increased over time.Conclusion: The prevalence of abdominal obesity and MS increased in Korean children and adolescents from 2007 to 2020. When analyzed by REF2022, both abdominal obesity and MS showed higher prevalence rates than when using REF2007, indicating that previous reports were underestimated. Follow-up for abdominal obesity and MS using REF2022 is needed.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 2","pages":"170-178"},"PeriodicalIF":5.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/b2/jomes-32-2-170.PMC10327689.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9817520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Constant Association between Low High-Density Lipoprotein Cholesterol and Gastric Cancer Regardless of Site. 低高密度脂蛋白胆固醇与胃癌的持续关联

IF 5.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Obesity & Metabolic Syndrome

Pub Date : 2023-06-30 DOI: 10.7570/jomes22045

Su Youn Nam, Jihyeon Jeong, Seong Woo Jeon

Background: Some epidemiologic factors and body mass index (BMI) have site-specific effects on gastric cancer. The site-specific effect of high-density lipoprotein cholesterol (HDL-C) and hyperglycemia on gastric cancer has not been reported.

Methods: This study included adults who underwent national gastric cancer screening in 2011 (n=5.49 million). The validation set included gastric cancer patients (n=3,262) and gastric cancer-free persons who underwent health screening (n=14,121) in a single hospital. The site-specific effects of metabolic components and epidemiologic factors on gastric cancer were investigated.

Results: Among 5.49 million individuals, 10,417 gastric cancer cases (6,764 non-cardiac gastric cancer [NCGC] and 152 cardiac gastric cancer [CGC]) were detected. BMI was inversely associated with NCGC (P for trend <0.001) but not with CGC. Low HDL-C was associated with both CGC (adjusted odds ratio [aOR], 1.90; 95% confidence interval [CI], 1.34 to 2.71) and NCGC (aOR, 1.41; 95% CI, 1.34 to 1.49). Fasting glucose ≥110 mg/dL was associated with NCGC (aOR, 1.19) and CGC (aOR, 1.50). Men predominance was larger in CGC (aOR, 3.28) than in NCGC (aOR, 1.98). Smoking, alcohol drinking, and family history were associated with NCGC but not with CGC. In the validation set, low HDL-C was associated with CGC (aOR, 2.80) and NCGC (aOR, 2.32). BMI was inversely associated with NCGC (P for trend <0.001), and hyperglycemia was positively associated with both NCGC and CGC.

Conclusion: Many epidemiologic factors had site-specific effects on gastric cancer, whereas low HDL-C and hyperglycemia were constantly associated with gastric cancer regardless of the site in two independent sets.

背景:一些流行病学因素和身体质量指数(BMI)对胃癌有部位特异性影响。高密度脂蛋白胆固醇(HDL-C)和高血糖对胃癌的部位特异性作用尚未见报道。方法:本研究纳入2011年接受全国胃癌筛查的成年人(n= 549万)。验证集包括在一家医院接受健康筛查的胃癌患者(n=3,262)和无胃癌患者(n=14,121)。研究了代谢成分和流行病学因素对胃癌的部位特异性影响。结果:549万人中，共检出胃癌10417例，其中非心源性胃癌6764例，心源性胃癌152例。结论:许多流行病学因素对胃癌有部位特异性影响，而低HDL-C和高血糖在两个独立的组中无论在什么部位都与胃癌持续相关。

{"title":"Constant Association between Low High-Density Lipoprotein Cholesterol and Gastric Cancer Regardless of Site.","authors":"Su Youn Nam, Jihyeon Jeong, Seong Woo Jeon","doi":"10.7570/jomes22045","DOIUrl":"https://doi.org/10.7570/jomes22045","url":null,"abstract":"Background: Some epidemiologic factors and body mass index (BMI) have site-specific effects on gastric cancer. The site-specific effect of high-density lipoprotein cholesterol (HDL-C) and hyperglycemia on gastric cancer has not been reported.Methods: This study included adults who underwent national gastric cancer screening in 2011 (n=5.49 million). The validation set included gastric cancer patients (n=3,262) and gastric cancer-free persons who underwent health screening (n=14,121) in a single hospital. The site-specific effects of metabolic components and epidemiologic factors on gastric cancer were investigated.Results: Among 5.49 million individuals, 10,417 gastric cancer cases (6,764 non-cardiac gastric cancer [NCGC] and 152 cardiac gastric cancer [CGC]) were detected. BMI was inversely associated with NCGC (P for trend <0.001) but not with CGC. Low HDL-C was associated with both CGC (adjusted odds ratio [aOR], 1.90; 95% confidence interval [CI], 1.34 to 2.71) and NCGC (aOR, 1.41; 95% CI, 1.34 to 1.49). Fasting glucose ≥110 mg/dL was associated with NCGC (aOR, 1.19) and CGC (aOR, 1.50). Men predominance was larger in CGC (aOR, 3.28) than in NCGC (aOR, 1.98). Smoking, alcohol drinking, and family history were associated with NCGC but not with CGC. In the validation set, low HDL-C was associated with CGC (aOR, 2.80) and NCGC (aOR, 2.32). BMI was inversely associated with NCGC (P for trend <0.001), and hyperglycemia was positively associated with both NCGC and CGC.Conclusion: Many epidemiologic factors had site-specific effects on gastric cancer, whereas low HDL-C and hyperglycemia were constantly associated with gastric cancer regardless of the site in two independent sets.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 2","pages":"141-150"},"PeriodicalIF":5.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/f4/jomes-32-2-141.PMC10327681.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9817526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis of Obesity: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity. 肥胖症的诊断:2022年韩国肥胖症研究学会肥胖症临床实践指南更新。

IF 5.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Obesity & Metabolic Syndrome

Pub Date : 2023-06-30 DOI: 10.7570/jomes23031

Ji-Hee Haam, Bom Taeck Kim, Eun Mi Kim, Hyuktae Kwon, Jee-Hyun Kang, Jung Hwan Park, Kyoung-Kon Kim, Sang Youl Rhee, Yang-Hyun Kim, Ki Young Lee

The prevalence of obesity has consistently increased worldwide, and many obesity-related diseases are emerging as major health problems. Body mass index (BMI) is used to define obesity and is highly correlated with body fat mass. Moreover, obesity-related morbidities increase linearly with the increase in BMI. The Korean Society for the Study of Obesity defined overweight as a BMI ≥23 kg/m² and obesity as a BMI ≥25 kg/m², based on a significant increase in obesity-related diseases. A waist circumference of ≥90 cm in men and ≥85 cm in women are defined as abdominal obesity, which is also correlated with obesity-related diseases. These diagnostic criteria are the same as in the previous version; however, the updated guidelines put greater emphasis on the use of morbidity as the basis for obesity and abdominal obesity diagnoses. These new guidelines will help to identify and manage high-risk groups for obesity-related comorbidities among Korean adults.

肥胖的患病率在世界范围内持续增加，许多与肥胖有关的疾病正在成为主要的健康问题。身体质量指数(BMI)被用来定义肥胖，并且与身体脂肪质量高度相关。此外，肥胖相关的发病率随着BMI的增加呈线性增加。韩国肥胖研究学会将BMI≥23 kg/m2定义为超重，BMI≥25 kg/m2定义为肥胖，这是基于肥胖相关疾病的显著增加。男性腰围≥90 cm、女性腰围≥85 cm被定义为腹部肥胖，腹部肥胖还与肥胖相关疾病相关。这些诊断标准与以前的版本相同;然而，更新的指南更加强调使用发病率作为肥胖和腹部肥胖诊断的基础。这些新的指南将有助于识别和管理韩国成年人中肥胖相关合并症的高危人群。

{"title":"Diagnosis of Obesity: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity.","authors":"Ji-Hee Haam, Bom Taeck Kim, Eun Mi Kim, Hyuktae Kwon, Jee-Hyun Kang, Jung Hwan Park, Kyoung-Kon Kim, Sang Youl Rhee, Yang-Hyun Kim, Ki Young Lee","doi":"10.7570/jomes23031","DOIUrl":"https://doi.org/10.7570/jomes23031","url":null,"abstract":"The prevalence of obesity has consistently increased worldwide, and many obesity-related diseases are emerging as major health problems. Body mass index (BMI) is used to define obesity and is highly correlated with body fat mass. Moreover, obesity-related morbidities increase linearly with the increase in BMI. The Korean Society for the Study of Obesity defined overweight as a BMI ≥23 kg/m2 and obesity as a BMI ≥25 kg/m2, based on a significant increase in obesity-related diseases. A waist circumference of ≥90 cm in men and ≥85 cm in women are defined as abdominal obesity, which is also correlated with obesity-related diseases. These diagnostic criteria are the same as in the previous version; however, the updated guidelines put greater emphasis on the use of morbidity as the basis for obesity and abdominal obesity diagnoses. These new guidelines will help to identify and manage high-risk groups for obesity-related comorbidities among Korean adults.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 2","pages":"121-129"},"PeriodicalIF":5.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/42/jomes-32-2-121.PMC10327686.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9766558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon. 2022年批准的抗肥胖药物KSSO指南和3期临床试验的承诺:天空和地平线上的抗肥胖药物。

IF 5.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Obesity & Metabolic Syndrome

Pub Date : 2023-06-30 DOI: 10.7570/jomes23032

Eonju Jeon, Ki Young Lee, Kyoung-Kon Kim

Obesity is a prevalent global health issue affecting approximately half of the world's population. Extensive scientific research highlights the urgent need for effective obesity management to mitigate health risks and prevent complications. While bariatric surgery has proven to be highly effective, providing substantial short-term and long-term weight loss and resolution of obesity-related comorbidities, it is important to recognize its limitations and associated risks. Given the global obesity epidemic and the limitations of surgical interventions, there is high demand for effective and safe anti-obesity medications (AOMs). In Korea, the Korean Society for the Study of Obesity strongly advocates for the use of pharmacotherapy in Korean adults with a body mass index of 25 kg/m² or higher who have not achieved weight reduction through non-pharmacological treatments. Currently, five AOMs have been approved for long-term weight management: orlistat, naltrexone/bupropion, phentermine/topiramate, liraglutide, and semaglutide. Tirzepatide is awaiting approval, and combination of semaglutide/cagrilintide and oral semaglutide are currently undergoing rigorous evaluation in phase 3 clinical trials. Furthermore, other promising drugs, including orforglipron, BI 456906, and retartrutide, are progressing to phase 3 studies, expanding the therapeutic options for obesity management. In personalized patient care, physicians play a crucial role in accurately identifying individuals who genuinely require pharmacotherapy and selecting appropriate AOMs based on individual patient characteristics. By integrating evidence-based interventions and considering the unique needs of patients, healthcare professionals significantly contribute to the success of obesity management strategies.

肥胖是一个普遍的全球健康问题，影响着世界上大约一半的人口。广泛的科学研究强调，迫切需要有效的肥胖管理，以减轻健康风险和预防并发症。虽然减肥手术已被证明是非常有效的，提供了大量的短期和长期的体重减轻和解决肥胖相关的合并症，但认识到其局限性和相关风险是很重要的。鉴于全球肥胖的流行和手术干预的局限性，对有效和安全的抗肥胖药物(AOMs)的需求很高。在韩国，韩国肥胖研究协会强烈主张对体重指数为25kg /m2或更高的韩国成年人使用药物治疗，这些成年人没有通过非药物治疗实现体重减轻。目前，有5种AOMs已被批准用于长期体重管理:奥利司他、纳曲酮/安非他酮、芬特明/托吡酯、利拉鲁肽和西马鲁肽。tizepatide正在等待批准，西马鲁肽/cagrilintide联合用药和口服西马鲁肽目前正在进行严格的3期临床试验评估。此外，其他有希望的药物，包括orforglipron, BI 456906和retartrutide，正在进行3期研究，扩大了肥胖管理的治疗选择。在个性化患者护理中，医生在准确识别真正需要药物治疗的个体和根据个体患者特征选择合适的aom方面发挥着至关重要的作用。通过整合循证干预措施并考虑患者的独特需求，医疗保健专业人员对肥胖管理策略的成功做出了重大贡献。

{"title":"Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon.","authors":"Eonju Jeon, Ki Young Lee, Kyoung-Kon Kim","doi":"10.7570/jomes23032","DOIUrl":"https://doi.org/10.7570/jomes23032","url":null,"abstract":"Obesity is a prevalent global health issue affecting approximately half of the world's population. Extensive scientific research highlights the urgent need for effective obesity management to mitigate health risks and prevent complications. While bariatric surgery has proven to be highly effective, providing substantial short-term and long-term weight loss and resolution of obesity-related comorbidities, it is important to recognize its limitations and associated risks. Given the global obesity epidemic and the limitations of surgical interventions, there is high demand for effective and safe anti-obesity medications (AOMs). In Korea, the Korean Society for the Study of Obesity strongly advocates for the use of pharmacotherapy in Korean adults with a body mass index of 25 kg/m2 or higher who have not achieved weight reduction through non-pharmacological treatments. Currently, five AOMs have been approved for long-term weight management: orlistat, naltrexone/bupropion, phentermine/topiramate, liraglutide, and semaglutide. Tirzepatide is awaiting approval, and combination of semaglutide/cagrilintide and oral semaglutide are currently undergoing rigorous evaluation in phase 3 clinical trials. Furthermore, other promising drugs, including orforglipron, BI 456906, and retartrutide, are progressing to phase 3 studies, expanding the therapeutic options for obesity management. In personalized patient care, physicians play a crucial role in accurately identifying individuals who genuinely require pharmacotherapy and selecting appropriate AOMs based on individual patient characteristics. By integrating evidence-based interventions and considering the unique needs of patients, healthcare professionals significantly contribute to the success of obesity management strategies.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 2","pages":"106-120"},"PeriodicalIF":5.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/d8/jomes-32-2-106.PMC10327684.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9753566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Diagnosis of Obesity: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity. 肥胖症的诊断:2022年韩国肥胖症研究学会肥胖症临床实践指南更新。

IF 5.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Obesity & Metabolic Syndrome

Pub Date : 2023-06-21 DOI: 10.7570/jome23031

Ji-Hee Haam, Bom Taeck Kim, Eun Mi Kim, Hyuktae Kwon, Jee-Hyun Kang, Jung Hwan Park, Kyoung-Kon Kim, Sang Youl Rhee, Yang-Hyun Kim, Ki Young Lee

The prevalence of obesity has consistently increased worldwide, and many obesity-related diseases are emerging as major health problems. Body mass index (BMI) is used to define obesity and is highly correlated with body fat mass. Moreover, obesity-related morbidities increase linearly with the increase in BMI. The Korean Society for the Study of Obesity defined overweight as a BMI ≥23 kg/m² and obesity as a BMI ≥25 kg/m², based on a significant increase in obesity-related diseases. A waist circumference of ≥90 cm in men and ≥85 cm in women are defined as abdominal obesity, which is also correlated with obesity-related diseases. These diagnostic criteria are the same as in the previous version; however, the updated guidelines put greater emphasis on the use of morbidity as the basis for obesity and abdominal obesity diagnoses. These new guidelines will help to identify and manage high-risk groups for obesity-related comorbidities among Korean adults.

肥胖的患病率在世界范围内持续增加，许多与肥胖有关的疾病正在成为主要的健康问题。身体质量指数(BMI)被用来定义肥胖，并且与身体脂肪质量高度相关。此外，肥胖相关的发病率随着BMI的增加呈线性增加。韩国肥胖研究学会将BMI≥23 kg/m2定义为超重，BMI≥25 kg/m2定义为肥胖，这是基于肥胖相关疾病的显著增加。男性腰围≥90 cm、女性腰围≥85 cm被定义为腹部肥胖，腹部肥胖还与肥胖相关疾病相关。这些诊断标准与以前的版本相同;然而，更新的指南更加强调使用发病率作为肥胖和腹部肥胖诊断的基础。这些新的指南将有助于识别和管理韩国成年人中肥胖相关合并症的高危人群。

{"title":"Diagnosis of Obesity: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity.","authors":"Ji-Hee Haam, Bom Taeck Kim, Eun Mi Kim, Hyuktae Kwon, Jee-Hyun Kang, Jung Hwan Park, Kyoung-Kon Kim, Sang Youl Rhee, Yang-Hyun Kim, Ki Young Lee","doi":"10.7570/jome23031","DOIUrl":"https://doi.org/10.7570/jome23031","url":null,"abstract":"The prevalence of obesity has consistently increased worldwide, and many obesity-related diseases are emerging as major health problems. Body mass index (BMI) is used to define obesity and is highly correlated with body fat mass. Moreover, obesity-related morbidities increase linearly with the increase in BMI. The Korean Society for the Study of Obesity defined overweight as a BMI ≥23 kg/m2 and obesity as a BMI ≥25 kg/m2, based on a significant increase in obesity-related diseases. A waist circumference of ≥90 cm in men and ≥85 cm in women are defined as abdominal obesity, which is also correlated with obesity-related diseases. These diagnostic criteria are the same as in the previous version; however, the updated guidelines put greater emphasis on the use of morbidity as the basis for obesity and abdominal obesity diagnoses. These new guidelines will help to identify and manage high-risk groups for obesity-related comorbidities among Korean adults.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9667258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glucose Control in Korean Patients with Type 2 Diabetes Mellitus according to Body Mass Index. 韩国2型糖尿病患者体重指数对血糖控制的影响

IF 5.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Obesity & Metabolic Syndrome

Pub Date : 2023-03-30 DOI: 10.7570/jomes22047

Ye-Lim Shin, Heesoh Yoo, Joo Young Hong, Jooeun Kim, Kyung-do Han, Kyu-Na Lee, Yang-Hyun Kim

Background: The prevalence of type 2 diabetes mellitus has continued to rise. Although many studies have focused on the connection between weight loss and glucose control, only a few studies have investigated the association between body mass index (BMI) and glucose control status. We examined the association between glucose control and obesity.

Methods: We analyzed 3,042 participants with diabetes mellitus who were aged ≥19 years when they participated in the 2014 to 2018 Korean National Health and Nutrition Examination Survey. The participants were divided into four groups according to their BMI (<18.5, 18.5-23, 23-25, and ≥25 kg/m²). We used guidelines from the Korean Diabetes Association to compare the glucose control in those groups, with a cross-sectional design, multivariable logistic regression, and glycosylated hemoglobin <6.5% as the reference.

Results: Overweight males aged ≥60 years had a high odds ratio (OR) for degraded glucose control (OR, 1.706; 95% confidence interval [CI], 1.151 to 2.527). Among obese females, those in the ≥60 years age group showed an increased OR for uncontrolled diabetes (OR, 1.516; 95% CI, 1.025 to 1.892). Moreover, in females, the OR for uncontrolled diabetes tended to increase as the BMI increased (P=0.017).

Conclusion: Obesity is associated with uncontrolled diabetes in female patients with diabetes who are aged ≥60 years. Physicians should closely monitor this group for diabetes control.

背景:2型糖尿病的患病率持续上升。虽然许多研究都集中在减肥和血糖控制之间的联系，但只有少数研究调查了体重指数(BMI)和血糖控制状态之间的关系。我们研究了血糖控制和肥胖之间的关系。方法:对参加2014 - 2018年韩国国民健康与营养调查的3042名年龄≥19岁的糖尿病患者进行分析。根据参与者的BMI分为四组(2)。我们使用韩国糖尿病协会的指南，通过横断面设计、多变量logistic回归和糖化血红蛋白来比较各组的血糖控制情况。结果:≥60岁的超重男性在降解血糖控制方面具有较高的优势比(OR) (OR, 1.706;95%可信区间[CI]， 1.151 ~ 2.527)。在肥胖女性中，≥60岁年龄组的未控制糖尿病OR增加(OR, 1.516;95% CI, 1.025 ~ 1.892)。此外，在女性中，未控制糖尿病的OR随着BMI的增加而增加(P=0.017)。结论:在年龄≥60岁的女性糖尿病患者中，肥胖与未控制的糖尿病相关。医生应密切监测这一群体的糖尿病控制情况。

{"title":"Glucose Control in Korean Patients with Type 2 Diabetes Mellitus according to Body Mass Index.","authors":"Ye-Lim Shin, Heesoh Yoo, Joo Young Hong, Jooeun Kim, Kyung-do Han, Kyu-Na Lee, Yang-Hyun Kim","doi":"10.7570/jomes22047","DOIUrl":"https://doi.org/10.7570/jomes22047","url":null,"abstract":"Background: The prevalence of type 2 diabetes mellitus has continued to rise. Although many studies have focused on the connection between weight loss and glucose control, only a few studies have investigated the association between body mass index (BMI) and glucose control status. We examined the association between glucose control and obesity.Methods: We analyzed 3,042 participants with diabetes mellitus who were aged ≥19 years when they participated in the 2014 to 2018 Korean National Health and Nutrition Examination Survey. The participants were divided into four groups according to their BMI (<18.5, 18.5-23, 23-25, and ≥25 kg/m2). We used guidelines from the Korean Diabetes Association to compare the glucose control in those groups, with a cross-sectional design, multivariable logistic regression, and glycosylated hemoglobin <6.5% as the reference.Results: Overweight males aged ≥60 years had a high odds ratio (OR) for degraded glucose control (OR, 1.706; 95% confidence interval [CI], 1.151 to 2.527). Among obese females, those in the ≥60 years age group showed an increased OR for uncontrolled diabetes (OR, 1.516; 95% CI, 1.025 to 1.892). Moreover, in females, the OR for uncontrolled diabetes tended to increase as the BMI increased (P=0.017).Conclusion: Obesity is associated with uncontrolled diabetes in female patients with diabetes who are aged ≥60 years. Physicians should closely monitor this group for diabetes control.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 1","pages":"55-63"},"PeriodicalIF":5.2,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/24/jomes-32-1-55.PMC10088554.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9288718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0